STAQ Pharma is working with the nonprofit scientific research organization IAVI to provide support services for the production of an innovative intranasal spray targeting COVID-19. This multi-partner project aims to produce a miniprotein anti-viral blocker delivered via an intranasal device. STAQ Pharma’s expertise in aseptic processing and experience with similar devices make them a key player in this project.

Working alongside IAVI and SK bioscience, STAQ Pharma will handle the fill-finish operations for the intranasal spray. The initial fill finish will take place in Denver, Colorado, utilizing STAQ’s cutting-edge 503B Outsourcing Facility, with the eventual production at STAQ’s contract manufacturing facility in Columbus, Ohio. Read more >